SCHEMBL1748058

SCHEMBL1748058

Cc1ccc2oc(S(C)(=O)=O)nc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.51
NPC1 O15118 8/20 0.51
RAB9A P51151 8/20 0.51
ALDH1A1 P00352 8/20 0.51
HPGD P15428 6/20 0.51
SMN1; SMN2 Q16637 4/20 0.51
HSD17B10 Q99714 4/20 0.51
TP53 P04637 3/20 0.51
CASP3 P42574 2/20 0.49
SENP7 Q9BQF6 2/20 0.49
SENP6 Q9GZR1 2/20 0.49
POLB P06746 1/20 0.49
SENP8 Q96LD8 1/20 0.49
MAPT P10636 7/20 0.45
FBP1 P09467 2/20 0.45
MMP2 P08253 1/20 0.44
MMP9 P14780 1/20 0.44
MMP8 P22894 1/20 0.44
MMP13 P45452 1/20 0.44
NFKB1 P19838 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31208297 1.00 KDM4E (0.51) KDM4ENPC1RAB9AALDH1A1HPGD
SCHEMBL1748081 0.86 KDM4E (0.53) KDM4ENPC1RAB9AALDH1A1HPGD
SCHEMBL18613864 0.81 FBP1 (0.44) KDM4ENPC1RAB9ASMN1; SMN2HSD17B10
SCHEMBL31208321 0.81 FBP1 (0.44) ALDH1A1SMN1; SMN2POLBMAPTFBP1
SCHEMBL1748273 0.81 FBP1 (0.44) ALDH1A1SMN1; SMN2POLBMAPTFBP1
SCHEMBL1748135 0.79 MAPT (0.51) KDM4ENPC1RAB9AALDH1A1HPGD
SCHEMBL1748015 0.79 SMN1; SMN2 (0.37) KDM4ENPC1RAB9AALDH1A1HPGD
SCHEMBL305334 0.77 LMNA (0.53) KDM4ENPC1RAB9AALDH1A1HPGD
SCHEMBL1747969 0.76 GAA (0.42) KDM4ENPC1RAB9AALDH1A1HPGD
SCHEMBL128635 0.76 FBP1 (0.61) KDM4ENPC1RAB9AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240409533-A1 HMOX1 INDUCERS Astellas Engineered Small Molecules US, Incorporated 2024-12-12 US disclosed
US-12071433-B2 HMOX1 inducers Astellas Engineered Small Molecules US, Incorporated (US) 2024-08-27 US disclosed
US-20240051952-A1 HMOX1 INDUCERS Astellas Engineered Small Molecules US, Incorporated 2024-02-15 US disclosed
US-20220177460-A1 HMOX1 INDUCERS Astellas Engineered Small Molecules US, Incorporated 2022-06-09 US disclosed
US-20220177460-A1 HMOX1 INDUCERS Astellas Engineered Small Molecules US, Incorporated 2022-06-09 US disclosed
EP-3952990-A1 HMOX1 INDUCERS Mitobridge, Inc. (US) 2022-02-16 EP disclosed
CN-113874074-A HMOX1 inducers 米托布里奇公司 2021-12-31 CN disclosed
WO-2020210339-A1 HMOX1 INDUCERS MITOBRIDGE, INC. (US) 2020-10-15 WO disclosed
WO-2020210339-A1 HMOX1 INDUCERS MITOBRIDGE, INC. (US) 2020-10-15 WO disclosed
US-10766888-B1 HMOX1 inducers MITOBRIDGE INC. (US) 2020-09-08 US disclosed
US-7968576-B2 Preparation and use of aryl alkyl acid derivatives for the treatment of obesity SMITH ROGER A 2011-06-28 US disclosed
US-20090270468-A1 Preparation and use of aryl alkyl acid derivatives for the treatment of obesity SMITH ROGER 2009-10-29 US disclosed
US-20090253762-A1 PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY SMITH ROGER 2009-10-08 US disclosed
US-20090197795-A1 PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY BAYER HEALTHCARE LLC (US) 2009-08-06 US disclosed
US-7423156-B2 Preparation and use of aryl alkyl acid derivatives for the treatment of obesity BAYER PHARMACEUTICALS CORPORATION (US) 2008-09-09 US disclosed
US-20060194859-A1 Preparation and use of aryl alkyl acid derivatives for the treatment of obesity BAYER PHARMACEUTICALS CORPORATION (US) 2006-08-31 US disclosed
US-7091228-B2 Preparation and use of aryl alkyl acid derivatives for the treatment of obesity BAYER PHARMACEUTICALS CORPORATION (US) 2006-08-15 US disclosed
EP-1633722-A2 PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY Bayer Pharmaceuticals Corporation (US) 2006-03-15 EP disclosed
WO-2004100881-A2 PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY BAYER PHARMACEUTICALS CORPORATION (US) 2004-11-25 WO disclosed
US-20040224997-A1 Preparation and use of aryl alkyl acid derivatives for the treatment of obesity BAYER PHARMACEUTICALS CORPORATION 2004-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224997-A1 Preparation and use of aryl alkyl acid derivatives for the treatment of obesity FABP4, GPR119, LIPC KDM4E 817/4885NPC1 187/4885RAB9A 2066/4885
US-10766888-B1 HMOX1 inducers HMOX1, HMOX2, HMBS KDM4E 2510/4885NPC1 3451/4885RAB9A 4748/4885
US-20060194859-A1 Preparation and use of aryl alkyl acid derivatives for the treatment of obesity FABP4, GPR119, LIPC KDM4E 817/4885NPC1 187/4885RAB9A 2066/4885
US-20090270468-A1 Preparation and use of aryl alkyl acid derivatives for the treatment of obesity FABP4, GPR119, LIPC KDM4E 817/4885NPC1 187/4885RAB9A 2066/4885
US-20240409533-A1 HMOX1 INDUCERS HMOX1, HMOX2, HMBS KDM4E 2510/4885NPC1 3451/4885RAB9A 4748/4885
US-12071433-B2 HMOX1 inducers HMOX1, HMOX2, HMBS KDM4E 2606/4885NPC1 3292/4885RAB9A 4725/4885
US-20240051952-A1 HMOX1 INDUCERS HMOX1, HMOX2, QSOX1 KDM4E 4001/4885NPC1 2622/4885RAB9A 4324/4885
US-20090197795-A1 PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY FABP4, GPR119, LIPC KDM4E 817/4885NPC1 187/4885RAB9A 2066/4885
US-20220177460-A1 HMOX1 INDUCERS HMOX1, HMOX2, HMBS KDM4E 2606/4885NPC1 3292/4885RAB9A 4725/4885
US-20090253762-A1 PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY FABP4, GPR119, LIPC KDM4E 817/4885NPC1 187/4885RAB9A 2066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.